Dual Adjuvant‐Loaded Peptide Antigen Self‐Assembly Potentiates Dendritic Cell‐Mediated Tumor Immunotherapy

Clinical translation of current cancer vaccine research has been hampered by limited antitumor immune responses due to inefficient antigen delivery and presentation, suboptimal DC and T cell activation. Biomaterial‐based nanovaccine offers targeted antigen delivery, protection from degradation in vi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advanced science Jg. 11; H. 36; S. e2403663 - n/a
Hauptverfasser:	Kim, Jaehyun, Kang, Seyoung, Kim, Jisu, Yong, Seok‐Beom, Lahiji, Shayan Fakhraei, Kim, Yong‐Hee
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Germany John Wiley & Sons, Inc 01.09.2024 John Wiley and Sons Inc Wiley
Schlagworte:	Acids Adjuvants Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - pharmacology Animals Antigen presentation Antigens, Neoplasm - immunology Apoptosis Breast cancer Cancer therapies Cancer vaccines Cancer Vaccines - administration & dosage Cancer Vaccines - immunology Cytokines Cytotoxicity dendritic cell immunotherapy Dendritic cells Dendritic Cells - immunology Disease Models, Animal Efficiency Female Humans immune checkpoint blockade Immune system Immunotherapy Immunotherapy - methods Kinases Lipids Lymphatic system Lymphocytes Melanoma Mice Mice, Inbred C57BL Peptides Peptides - chemistry Peptides - immunology self‐assembly Survivin - immunology therapeutic cancer vaccine tumor‐associated antigen tumor‐associated antigen dendritic cell immunotherapy immune checkpoint blockade self‐assembly therapeutic cancer vaccine
ISSN:	2198-3844, 2198-3844
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!